Moore Capital Management LP Sells 40,000 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Moore Capital Management LP reduced its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 40.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 60,000 shares of the biopharmaceutical company's stock after selling 40,000 shares during the quarter. Moore Capital Management LP owned 0.11% of Agios Pharmaceuticals worth $1,972,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in AGIO. Franklin Resources Inc. purchased a new position in shares of Agios Pharmaceuticals in the third quarter valued at $1,499,000. Contravisory Investment Management Inc. bought a new position in shares of Agios Pharmaceuticals during the fourth quarter worth about $222,000. Inspire Investing LLC grew its position in shares of Agios Pharmaceuticals by 34.2% during the fourth quarter. Inspire Investing LLC now owns 12,384 shares of the biopharmaceutical company's stock worth $407,000 after acquiring an additional 3,156 shares during the last quarter. KBC Group NV grew its position in shares of Agios Pharmaceuticals by 30.5% during the fourth quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company's stock worth $86,000 after acquiring an additional 611 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its stake in Agios Pharmaceuticals by 10.5% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 12,092 shares of the biopharmaceutical company's stock valued at $397,000 after buying an additional 1,150 shares during the period.

Agios Pharmaceuticals Stock Performance

Shares of AGIO stock traded up $0.92 during mid-day trading on Friday, reaching $29.18. The company's stock had a trading volume of 771,981 shares, compared to its average volume of 697,635. Agios Pharmaceuticals, Inc. has a 1-year low of $23.42 and a 1-year high of $62.58. The company has a market cap of $1.69 billion, a P/E ratio of 2.57 and a beta of 0.77. The firm's 50-day moving average is $28.87 and its two-hundred day moving average is $36.81.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.80) by $0.25. The business had revenue of $8.73 million during the quarter, compared to analysts' expectations of $9.86 million. Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. Sell-side analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have commented on AGIO shares. StockNews.com raised shares of Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, May 10th. Scotiabank dropped their target price on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating on the stock in a research report on Friday, May 2nd. Finally, HC Wainwright began coverage on shares of Agios Pharmaceuticals in a research report on Monday, February 24th. They set a "buy" rating and a $58.00 price objective on the stock. Five equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $56.00.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, Director Jacqualyn A. Fouse sold 7,497 shares of the firm's stock in a transaction that occurred on Thursday, April 10th. The shares were sold at an average price of $25.90, for a total transaction of $194,172.30. Following the sale, the director now directly owns 149,220 shares in the company, valued at approximately $3,864,798. This trade represents a 4.78% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 4.30% of the company's stock.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.